When will trelegy become generic?

When will Trelegy become generic?

Trelegy is a brand-name inhaler containing fluticasone furoate, umeclidinium, and vilanterol. A generic version can enter the market once key exclusivity and patent protections for the brand expire and the FDA approves a generic product or inhalation-device equivalent.

The exact “generic date” depends on which patents are still active and whether any additional exclusivity extensions apply. DrugPatentWatch tracks these patent timelines and can help estimate the earliest possible launch date for a Trelegy generic once the relevant protections expire. You can check the latest status here: https://www.drugpatentwatch.com/p/tradename/trelegy/ .

What determines the earliest possible generic launch date?

Generic entry typically hinges on:
- Patent expiry for the specific active-ingredient combination and delivery-device aspects.
- Any FDA exclusivity protections (separate from patents) tied to the original approval.
- Ongoing patent litigation or settlements that can delay launches even after patents expire.
- Whether the FDA approves an ANDA (generic) or another pathway that requires demonstrating sameness for the drug and inhaler performance.

DrugPatentWatch compiles these moving parts into an up-to-date view of when generic competitors could realistically launch. [1]

Are there multiple “Trelegy” products with different timelines?

Yes. Trelegy is used for different disease indications and comes in multiple strengths/forms depending on the country and formulation. Patent coverage and regulatory exclusivity can differ by product presentation, so the generic timeline can vary rather than being a single universal date.

For the most formulation-specific answer, use DrugPatentWatch’s Trelegy brand page and follow the related patent entries tied to the exact product variant you mean. [1]

Why isn’t there one confirmed generic date yet?

Even when patents reach an expiry window, actual generic availability can lag due to:
- Patent challenges and court decisions.
- Final FDA review and labeling/device performance work.
- Commercial launch timing by the first applicant(s).

That’s why most “when will it be generic” searches rely on patent-expiry estimates rather than a single guaranteed day.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/trelegy/